The Medipass operation achieved a revenue run rate for the 12-months to end February 2021 of
approximately $1.8 million and generated an EBITDA loss over that 12-month period of approximately
$1.5 million.
Obviously a strategic move, and important. It will be interesting to see what Tyro financials look like at year end.
Ann: Tyro to Acquire Health Fintech - Medipass, page-7
Add TYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.5¢ |
Change
-0.010(1.06%) |
Mkt cap ! $490.5M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.8¢ | 91.0¢ | $2.343M | 2.508M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12450 | 93.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 12287 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| TYR (ASX) Chart |